Placebo-Controlled Trial of Cytisine for Smoking Cessation
- 28 September 2011
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 365 (13), 1193-1200
- https://doi.org/10.1056/NEJMoa1102035
Abstract
BACKGROUND Cytisine, a partial agonist that binds with high affinity to the alpha(4)beta(2) nicotinic acetylcholine receptor, is a low-cost treatment that may be effective in aiding smoking cessation. This study assessed the efficacy and safety of cytisine as compared with placebo. METHODS We conducted a single-center, randomized, double-blind, placebo-controlled trial. Participants were randomly assigned to receive cytisine or matching placebo for 25 days; participants in both groups received a minimal amount of counseling during the study. The primary outcome measure was sustained, biochemically verified smoking abstinence for 12 months after the end of treatment. Of 1542 adult smokers screened, 740 were enrolled and 370 were randomly assigned to each study group. RESULTS The rate of sustained 12-month abstinence was 8.4% (31 participants) in the cytisine group as compared with 2.4% (9 participants) in the placebo group (difference, 6.0 percentage points; 95% confidence interval [CI], 2.7 to 9.2; P = 0.001). The 7-day point prevalence for abstinence at the 12-month follow-up was 13.2% in the cytisine group versus 7.3% in the placebo group (P= 0.01). Gastrointestinal adverse events were reported more frequently in the cytisine group (difference, 5.7 percentage points; 95% CI, 1.2 to 10.2). CONCLUSIONS In this single-center study, cytisine was more effective than placebo for smoking cessation. The lower price of cytisine as compared with that of other pharmacotherapies for smoking cessation may make it an affordable treatment to advance smoking cessation globally. (Funded by the National Prevention Research Initiative and others; Current Controlled Trials number, ISRCTN37568749.)This publication has 17 references indexed in Scilit:
- Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependenceBritish Journal of Pharmacology, 2010
- Nicotinic Acetylcholine Receptors in the Mesolimbic Pathway: Primary Role of Ventral Tegmental Area α6β2* Receptors in Mediating Systemic Nicotine Effects on Dopamine Release, Locomotion, and ReinforcementJournal of Neuroscience, 2010
- Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessationExpert Opinion on Investigational Drugs, 2008
- A Double-Blind, Randomised, Placebo-Controlled Trial of Cytisine for Smoking Cessation in Medium-Dependent WorkersJournal of Smoking Cessation, 2008
- Cytisine for smoking cessation: A research agendaDrug and Alcohol Dependence, 2008
- An uncontrolled trial of cytisine (Tabex) for smoking cessationTobacco Control, 2006
- Mortality in relation to smoking: 50 years' observations on male British doctorsBMJ, 2004
- Shape of the relapse curve and long‐term abstinence among untreated smokersAddiction, 2003
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991
- Assessment of Depression: The Depression InventoryModern problems of pharmacopsychiatry, 1973